A Systems Approach to Rheumatoid Arthritis

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  You, Sungyong ^a   Cho, Chul Soo ^b,c   Lee, Inyoul ^d   Hood, Leroy ^d   Hwang, Daehee ^a   Kim, Wan Uk ^b,c  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANGIOGENESIS; ARTICLE; BONE DESTRUCTION; CELL FUNCTION; CELL PROLIFERATION; DISEASE MARKER; DOWN REGULATION; FIBROBLAST; GENE ACTIVATION; GENE EXPRESSION; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; OSTEOARTHRITIS; PATHOGENESIS; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; TRANSCRIPTION REGULATION; UPREGULATION;

ARTHRITIS, RHEUMATOID; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; MOLECULAR TARGETED THERAPY; OSTEOARTHRITIS; SYNOVIAL MEMBRANE; SYSTEMS BIOLOGY; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871122759     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051508     Document Type: Article

References (57)

1. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, et al. (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43: 250-258.
2. Firestein GS, (2003) Evolving concepts of rheumatoid arthritis. Nature 423: 356-361.
3. McInnes IB, Liew FY, (2005) Cytokine networks-towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 1: 31-39.
4. Huber R, Hummert C, Gausmann U, Pohlers D, Koczan D, et al. (2008) Identification of intra-group, inter-individual, and gene-specific variances in mRNA expression profiles in the rheumatoid arthritis synovial membrane. Arthritis Res Ther 10: R98.
5. Kraan TCTMV, van Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJM, et al. (2003) Rheumatoid arthritis is a heterogeneous disease- Evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 48: 2132-2145.
6. Ungethuem U, Haeupl T, Witt H, Koczan D, Krenn V, et al. (2010) Molecular signatures and new candidates to target the pathogenesis of rheumatoid arthritis. Physiol Genomics 42A: 267-282.
7. Wu ZJ, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F, (2004) A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 99: 909-917.
8. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
9. Kim Y, Kim TK, Kim Y, Yoo J, You S, et al. (2011) Principal network analysis: identification of subnetworks representing major dynamics using gene expression data. Bioinformatics 27: 391-398.
10. Nakazato T, Bono H, Matsuda H, Takagi T, (2009) Gendoo: functional profiling of gene and disease features using MeSH vocabulary. Nucleic acids research 37: W166-169.
11. Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, et al. (2004) Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res 32: D497-501.
12. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, et al. (2006) BioGRID: a general repository for interaction datasets. Nucleic Acids Res 34: D535-539.
13. von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, et al. (2003) STRING: a database of predicted functional associations between proteins. Nucleic Acids Res 31: 258-261.
14. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, et al. (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27: 29-34.
15. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
16. Zhao F, Xuan Z, Liu L, Zhang MQ, (2005) TRED: a Transcriptional Regulatory Element Database and a platform for in silico gene regulation studies. Nucleic Acids Res 33: D103-107.
17. Severin J, Waterhouse AM, Kawaji H, Lassmann T, van Nimwegen E, et al. (2009) FANTOM4 EdgeExpressDB: an integrated database of promoters, genes, microRNAs, expression dynamics and regulatory interactions. Genome Biol 10: R39.
18. Linhart C, Halperin Y, Shamir R, (2008) Transcription factor and microRNA motif discovery: the Amadeus platform and a compendium of metazoan target sets. Genome Res 18: 1180-1189.
19. Ryu T, Jung J, Lee S, Nam HJ, Hong SW, et al. (2007) bZIPDB: a database of regulatory information for human bZIP transcription factors. BMC genomics 8: 136.
20. Montgomery SB, Griffith OL, Sleumer MC, Bergman CM, Bilenky M, et al. (2006) ORegAnno: an open access database and curation system for literature-derived promoters, transcription factor binding sites and regulatory variation. Bioinformatics 22: 637-640.
21. Sakkas LI, Platsoucas CD, (2007) The role of T cells in the pathogenesis of osteoarthritis. Arthritis Rheum 56: 409-424.
22. Huang DW, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
23. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, et al. (2002) Arthritis critically dependent on innate immune system players. Immunity 16: 157-168.
24. Janossy G, Panayi G, Duke O, Bofill M, Poulter LW, et al. (1981) Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 2: 839-842.
25. Farahat MN, Yanni G, Poston R, Panayi GS, (1993) Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 52: 870-875.
26. Imamura F, Aono H, Hasunuma T, Sumida T, Tateishi H, et al. (1998) Monoclonal expansion of synoviocytes in rheumatoid arthritis. Arthritis Rheum 41: 1979-1986.
27. Koch AE, (1998) Angiogenesis- Implications for rheumatoid arthritis. Arthritis Rheum 41: 951-962.
28. Firestein GS, (1996) Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum 39: 1781-1790.
29. Meyer LH, Franssen L, Pap T, (2006) The role of mesenchymal cells in the pathophysiology of inflammatory arthritis. Best Pract Res Clin Rheumatol 20: 969-981.
30. Tolboom TC, Zhang YH, Henriquez NV, Nelissen RG, Toes RE, et al. (2006) Fibroblast-like synoviocytes from patients with rheumatoid arthritis are more sensitive to apoptosis induced by the viral protein, apoptin, than fibroblast-like synoviocytes from trauma patients. Clin Exp Rheumatol 24: 142-147.
31. Kasperkovitz PV, Timmer TC, Smeets TJ, Verbeet NL, Tak PP, et al. (2005) Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis. Arthritis Rheum 52: 430-441.
32. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, et al. (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 285: 9262-9272.
33. van Baarsen LG, Wijbrandts CA, Timmer TC, van der Pouw Kraan TC, Tak PP, et al. (2010) Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood. Arthritis Rheum 62: 1602-1607.
34. Kremer JM, Tony H, Tak PP, Luggen M, Manette X, et al. (2006) Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors. Ann Rheum Dis 65: 326-326.
35. Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, et al. (2008) Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthrit Rheum-Arthr 59: 785-793.
36. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, et al. (2009) Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 68: 216-221.
37. Buch MH, Bingham SJ, Seto Y, McGonagle D, Bejarano V, et al. (2004) Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum 50: 725-728.
38. Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, et al. (2007) Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445: 931-935.
39. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, et al. (2007) Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445: 936-940.
40. Josefowicz SZ, Lu LF, Rudensky AY, (2012) Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 30: 531-564.
41. Woolf E, Xiao C, Fainaru O, Lotem J, Rosen D, et al. (2003) Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci USA 100: 7731-7736.
42. Komine O, Hayashi K, Natsume W, Watanabe T, Seki Y, et al. (2003) The Runx1 transcription factor inhibits the differentiation of naive CD4+ T cells into the Th2 lineage by repressing GATA3 expression. J Exp Med 198: 51-61.
43. Han Z, Boyle DL, Manning AM, Firestein GS, (1998) AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28: 197-208.
44. Kinne RW, Boehm S, Iftner T, Aigner T, Vornehm S, et al. (1995) Synovial fibroblast-like cells strongly express jun-B and C-fos proto-oncogenes in rheumatoid- and osteoarthritis. Scand J Rheumatol, Suppl 101: 121-125.
45. Shiozawa S, Shimizu K, Tanaka K, Hino K, (1997) Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J Clin Invest 99: 1210-1216.
46. Tak PP, Gerlag DM, Aupperle KR, Aupperle KR, van de Geest DA, et al. (2001) Inhibitor of nuclear factor kappa B kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 44: 1897-1907.
47. Sanders M, (2000) A review of controlled clinical trials examining the effects of antimalarial compounds and gold compounds on radiographic progression in rheumatoid arthritis. J Rheumatol 27: 523-529.
48. Jeon KI, Jeong JY, Jue DM, (2000) Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J Immunol 164: 5981-5989.
49. Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR, (1997) Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis (RA) synovium. Arthritis Rheum 40: 255-255.
50. Inazuka M, Tahira T, Horiuchi T, Harashima S, Sawabe T, et al. (2000) Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium. Rheumatology 39: 262-266.
51. Reme T, Travaglio A, Gueydon E, Adla L, Jorgensen C, et al. (1998) Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue. Clin Exp Immunol 111: 353-358.
52. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, et al. (2002) Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 99: 10025-10030.
53. Tamamura H, Tsutsumi H, Masuno H, Fujii N, (2007) Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Curr Med Chem 14: 93-102.
54. Tedder TF, (2009) CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 5: 572-577.
55. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, et al. (2010) Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 62: 1849-1861.
56. Yoon HJ, You S, Yoo SA, Kim NH, Kwon HM, et al. (2011) NF-AT5 Is a Critical Regulator of Inflammatory Arthritis. Arthritis Rheum 63: 1843-1852.
57. Cash JM, Klippel JH, (1994) Second-line drug therapy for rheumatoid arthritis. The New England journal of medicine 330: 1368-1375.